PTC Therapeutics chief commercial officer stepping down
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback
Infographic: The Big Picture 2023 Sustainability Outlook
The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism
Mark Rothera agreed to step down as chief commercial officer of PTC Therapeutics Inc., effective Aug. 9.
Rothera entered into a consulting agreement, effective Aug. 10, 2017, with a term continuing through Sept. 30, 2018.
